Kiniksa Pharmaceuticals Ltd.(KNSA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KNSA Kiniksa Pharmaceuticals Ltd.

交易中 10-08 15:30:32 EDT

78.39

+0.43

+0.55%

最高78.40	最低75.54	成交量23.70万
今开77.18	昨收77.96	日振幅3.67%
总市值61.16亿	流通市值31.31亿	总股本7,802万
成交额1,825万	换手率0.59%	流通股本3,994万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KNSA","market":"US","secType":"STK","nameCN":"Kiniksa Pharmaceuticals Ltd.","latestPrice":78.39,"timestamp":1791487828389,"preClose":77.96,"halted":0,"volume":237018,"delay":0,"changeRate":0.005515649050795368,"floatShares":39941500,"shares":78024013,"eps":0.99,"marketStatus":"交易中","change":0.43,"latestTime":"10-08 15:30:32 EDT","open":77.18,"high":78.4,"low":75.54,"amount":18249443.85345,"amplitude":0.036685,"askPrice":78.4,"askSize":310,"bidPrice":78.2,"bidSize":5,"shortable":3,"etf":0,"ttmEps":0.99,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1527134400000,"exchange":"NASDAQ","adjPreClose":77.96,"preHourTrading":{"tag":"盘前","latestPrice":77.9,"preClose":77.96,"latestTime":"08:35 EDT","volume":57,"amount":4443.26001,"timestamp":1791462900129,"change":-0.06,"changeRate":-0.00077,"amplitude":0.03335},"postHourTrading":{"tag":"盘后","latestPrice":78.5,"preClose":77.96,"latestTime":"19:30 EDT","volume":13783,"amount":1074820.76,"timestamp":1791415802722,"change":0.54,"changeRate":0.006927,"amplitude":0.006927},"volumeRatio":0.532087,"impliedVol":0.4891,"impliedVolPercentile":0.6056},"requestUrl":"/m/hq/s/KNSA","defaultTab":"news","newsList":[{"id":"2654388397","title":"Kiniksa（KNSA）上调全年收入指引 KPL-387药物启动三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2654388397","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654388397?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:36","pubTimestamp":1785249419,"startTime":"0","endTime":"0","summary":"金吾财讯 | Kiniksa Pharmaceuticals 公布2026年第二季度财报，公司上调全年营收预期，同时核心在研药物KPL-387正式进入三期临床试验阶段。临床管线迎来重要进展，针对复发性心包炎的候选药物KPL-387启动代号为PASTORALE的三期试验，试验已经开启患者招募与给药工作。管理层预估KPL-387有望在2028至2029年实现商业化上市，为相关病症带来新的治疗方案。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","KNSA","IBBJ","BK4139","PSYK","MDTX","BK4505","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118500245","title":"异动解读 | Kiniksa制药盘中大涨12.74%，因上调收入指引及披露研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1118500245","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118500245?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:03","pubTimestamp":1777385011,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals Ltd.（KNSA）今日盘中大涨12.74%，引起了市场的广泛关注。消息面上，公司宣布上调其2026财年核心产品Arcalyst的净收入指引区间至9.3亿至9.45亿美元，这一积极修正反映了公司对该药物市场表现和未来增长潜力的强劲信心，是推动股价上涨的关键因素。此外，公司还披露了其研发药物KPL-387的二期临床试验数据预计在2026年下半年公布，并计划在今年年底前启动三期临床试验，显示了研发管线的稳步推进。同时，公司稳健的财务状况也为股价提供了支撑。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KNSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124510876","title":"异动解读 | Kiniksa制药盘前大涨8.67%，因上调Arcalyst收入指引及披露研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1124510876","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124510876?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:37","pubTimestamp":1777376277,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals Ltd.今日盘前股价大涨8.67%，引起了市场的广泛关注。消息面上，公司宣布上调其2026财年核心产品Arcalyst的净收入指引区间至9.3亿至9.45亿美元，这一积极修正反映了公司对该药物市场表现和未来增长潜力的强劲信心，是推动股价上涨的关键因素。同时，公司截至2026年3月31日持有的现金及短期投资总额达4.681亿美元，展现了稳健的财务状况，为公司的持续运营和未来发展提供了有力支撑。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KNSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157886700","title":"Kiniksa制药KPL-387二期数据预计2026年下半年公布 三期试验将于年底前启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1157886700","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157886700?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:34","pubTimestamp":1777376088,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals Ltd. 宣布其研发药物KPL-387的二期临床试验数据预计在2026年下半年公布。此外，公司计划在今年年底前启动该药物的三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNSA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171882737","title":"Kiniksa Pharmaceuticals Ltd. 2026年3月31日现金及短期投资达4.681亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171882737","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171882737?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:34","pubTimestamp":1777376053,"startTime":"0","endTime":"0","summary":"截至2026年3月31日，Kiniksa Pharmaceuticals Ltd. (KNSA) 持有的现金及短期投资总额为4.681亿美元。这一财务数据展现了公司在报告期末的资金储备状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNSA","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137071546","title":"Kiniksa制药上调2026年Arcalyst产品净收入指引至9.3-9.45亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137071546","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137071546?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:32","pubTimestamp":1777375977,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals Ltd. (KNSA) 宣布调整其2026财年的财务预期，将核心产品Arcalyst的净收入指引区间提升至9.3亿至9.45亿美元。这一修正反映出公司对该药物市场表现和未来增长潜力的强劲信心。\n此次指引上调基于Arcalyst在自身炎症性疾病治疗领域的持续商业化成功以及不断扩大的市场接纳度。公司管理层指出，该调整也考虑了当前积极的处方趋势和预期的市场需求增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KNSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516299634","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 快速上涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516299634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516299634?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:36","pubTimestamp":1741012575,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时36分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价大幅上涨5.37%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为0.14%。其相关个股中，Sunshine Biopharma Inc C/Wts 、Scilex Holding Company、Intercure Ltd.涨幅较大，苏轩堂、Petros Pharmaceuticals, Inc.、大自然药业较为活跃，换手率分别为6.22%、2.94%、2.48%，振幅较大的相关个股有Redhill Biopharma Ltd、Organogenesis Holdings Inc.、Scilex Holding Company，振幅分别为7.50%、7.09%、6.36%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223616abe634c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223616abe634c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KNSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516552227","title":"Kiniksa Pharmaceuticals, Ltd.2024财年实现净利润-43.19百万美元，同比减少406.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516552227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516552227?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:00","pubTimestamp":1740844859,"startTime":"0","endTime":"0","summary":"3月2日，Kiniksa Pharmaceuticals, Ltd.公布财报，公告显示公司2024财年净利润为-43.19百万美元，同比减少406.75%；其中营业收入为4.23亿美元，同比增加56.67%，每股基本收益为-0.60美元。从资产负债表来看，Kiniksa Pharmaceuticals, Ltd.总负债1.42亿美元，其中短期债务1.99百万美元，资产负债比为4.10，流动比率为3.29。机构评级：截至2025年3月2日，当前有5家机构对Kiniksa Pharmaceuticals, Ltd.目标价做出预测，其中目标均价为34.20美元，其中最低目标价为30.00美元，最高目标价为40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000115a259dc9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000115a259dc9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136511510","title":"Kiniksa Pharmaceuticals 2024年第四季度GAAP每股收益$(0.12)与$0.04预估不相符，销售额$1.2254亿未达到$1.2338亿预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1136511510","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136511510?lang=zh_cn&edition=full","pubTime":"2025-02-25 20:40","pubTimestamp":1740487253,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals报告季度每股亏损$，低于分析师一致预期的$0.04，下降了400%。去年同期每股收益为$0.35，同比下降了134.29%。公司报告季度销售额为$1.2254亿，未达到分析师一致预期的$1.2338亿，同比下降了0.68%。以上内容来自Benzinga Earnings专栏，原文如下：Kiniksa Pharmaceuticals  reported quarterly losses of $ per share which missed the analyst consensus estimate of $0.04 by 400 percent. This is a 134.29 percent decrease over earnings of $0.35 per share from the same period last year.  The company reported quarterly sales of $122.54 million which missed the analyst consensus estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kiniksa Pharmaceuticals 2024年第四季度GAAP每股收益$(0.12)与$0.04预估不相符，销售额$1.2254亿未达到$1.2338亿预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510380357","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 急速跳水5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510380357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510380357?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:34","pubTimestamp":1739284460,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时34分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价快速下跌5.31%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为0.20%。其相关个股中，Evoke Pharma, Inc.、博美集团、Akanda Corp.涨幅较大，大自然药业、Quantum Biopharma Ltd.、Cbdmd, Inc.较为活跃，换手率分别为13.48%、2.63%、0.58%，振幅较大的相关个股有Incannex Healthcare Inc.、Organigram Holdings Inc.、Evoke Pharma, Inc.，振幅分别为6.28%、5.17%、5.17%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223420abcb06cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223420abcb06cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509206868","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大涨5.40%报20.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509206868","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509206868?lang=zh_cn&edition=full","pubTime":"2025-02-07 00:26","pubTimestamp":1738859184,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日00时26分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价快速拉升5.40%。截至发稿，该股报20.69美元/股，成交量14.2226万股，换手率0.20%，振幅5.55%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为1.92%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207002624a23be780&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207002624a23be780&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KNSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509723585","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 早盘急速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509723585","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509723585?lang=zh_cn&edition=full","pubTime":"2025-02-05 23:57","pubTimestamp":1738771075,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日23时57分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价快速拉升5.02%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为1.12%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205235755987b8bb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205235755987b8bb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KNSA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503589114","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大跌8.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503589114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503589114?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:31","pubTimestamp":1736778710,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时31分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价快速下挫8.43%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为0.42%。其相关个股中，Intra-Cellular Therapies Inc.、Citius Oncology, Inc.、Avadel Pharmaceuticals Plc涨幅较大，Intra-Cellular Therapies Inc.、Cbdmd, Inc.、大自然药业较为活跃，换手率分别为4.03%、3.33%、0.86%，振幅较大的相关个股有Sunshine Biopharma Inc.、Painreform Ltd.、Petros Pharmaceuticals, Inc.，振幅分别为99.66%、98.89%、7.71%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223150aba93080&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223150aba93080&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KNSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2491358806","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大跌5.02%报20.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491358806","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2491358806?lang=zh_cn&edition=full","pubTime":"2024-12-13 01:53","pubTimestamp":1734026002,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日01时53分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价大幅下挫5.02%。截至发稿，该股报20.18美元/股，成交量7.8649万股，换手率0.11%，振幅4.00%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为1.08%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213015322ab7304b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213015322ab7304b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FLGC","BK4539","KNSA","BK4505","BK4139","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488975317","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大跌5.13%报20.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488975317","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2488975317?lang=zh_cn&edition=full","pubTime":"2024-12-04 04:31","pubTimestamp":1733257905,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日04时31分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价急速跳水5.13%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为0.91%。其相关个股中，Citius Oncology, Inc.、Medicus Pharma Ltd.、Sunshine Biopharma Inc C/Wts 涨幅较大，Citius Oncology, Inc.、Painreform Ltd.、大自然药业较为活跃，换手率分别为140.57%、40.75%、39.33%，振幅较大的相关个股有Citius Oncology, Inc.、Medicus Pharma Ltd.、Sunshine Biopharma Inc C/Wts ，振幅分别为116.67%、45.51%、32.53%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204043145971b6d22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204043145971b6d22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDCX","KNSA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481930721","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 急速上涨5.04%报23.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481930721","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481930721?lang=zh_cn&edition=full","pubTime":"2024-11-07 03:37","pubTimestamp":1730921874,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日03时37分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价大幅拉升5.04%。截至发稿，该股报23.14美元/股，成交量35.0814万股，换手率0.49%，振幅4.36%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为2.43%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107033754971a4dbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107033754971a4dbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KNSA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2480819875","title":"Kiniksa Pharmaceuticals, Ltd.2024财年第三财季实现净利润-12.69百万美元，同比增加8.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480819875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2480819875?lang=zh_cn&edition=full","pubTime":"2024-11-03 00:01","pubTimestamp":1730563288,"startTime":"0","endTime":"0","summary":"11月3日，Kiniksa Pharmaceuticals, Ltd.公布财报，公告显示公司2024财年第三财季净利润为-12.69百万美元，同比增加8.44%；其中营业收入为1.12亿美元，同比增加67.04%，每股基本收益为-0.18美元。从资产负债表来看，Kiniksa Pharmaceuticals, Ltd.总负债1.18亿美元，其中短期债务2.03百万美元，资产负债比为4.71，流动比率为0.04。机构评级：截至2024年11月3日，当前有6家机构对Kiniksa Pharmaceuticals, Ltd.目标价做出预测，其中目标均价为35.83美元，其中最低目标价为32.00美元，最高目标价为40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000227ab98f592&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000227ab98f592&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2479283855","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 早盘急速下挫17.94%报22.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479283855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2479283855?lang=zh_cn&edition=full","pubTime":"2024-10-29 21:32","pubTimestamp":1730208750,"startTime":"0","endTime":"0","summary":"北京时间2024年10月29日21时32分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价大幅下挫17.94%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为0.14%。其相关个股中，Shuttle Pharmaceuticals Holdings, Inc.、Cyclo Therapeutics, Inc.、Im Cannabis Corp.涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Evoke Pharma, Inc.、Mira Pharmaceuticals, Inc.较为活跃，换手率分别为491.86%、13.90%、3.93%，振幅较大的相关个股有Shuttle Pharmaceuticals Holdings, Inc.、Kiniksa Pharmaceuticals, Ltd.、苏轩堂，振幅分别为10.35%、9.01%、4.76%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102921323095bd820f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102921323095bd820f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2468387501","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 临近午盘股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468387501","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2468387501?lang=zh_cn&edition=full","pubTime":"2024-09-19 23:32","pubTimestamp":1726759927,"startTime":"0","endTime":"0","summary":"北京时间2024年09月19日23时32分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价快速拉升5.07%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为0.01%。其相关个股中，Flora Growth Corp.、Sunshine Biopharma Inc C/Wts 、Scilex Holding Company涨幅较大，Sunshine Biopharma Inc.、Sonoma Pharmaceuticals, Inc.、Painreform Ltd.较为活跃，换手率分别为171.73%、98.24%、22.20%，振幅较大的相关个股有Bright Green Corporation、Flora Growth Corp.、Petros Pharmaceuticals, Inc.，振幅分别为66.17%、18.10%、17.87%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091923320798e38215&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091923320798e38215&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA","BK4139","BK4539","FLGC","BK4505","BK4183"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kiniksa.com","stockEarnings":[{"period":"1week","weight":0.0449},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.1924},{"period":"6month","weight":0.6559},{"period":"1year","weight":1.0451},{"period":"ytd","weight":0.8899}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.1439},{"period":"1year","weight":0.1616},{"period":"ytd","weight":0.1398}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kiniksa Pharmaceuticals International, plc于2015年7月21日在百慕大成立。该公司于2024年6月28日将公司注册地由百慕大变更为英国。该公司是一家生物制药公司，专注于发现、获取、开发和商业化治疗药物，为患有严重未满足医疗需求的使人衰弱的疾病的患者提供治疗药物。该公司的免疫调节组合ARCALYST、KPL-404和mavrilimumab基于强大的生物学原理或经过验证的机制，针对一系列未得到充分治疗的心血管和自身免疫疾病，并提供差异化的潜力。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.005937},{"month":2,"riseRate":0.75,"avgChangeRate":0.046662},{"month":3,"riseRate":0.375,"avgChangeRate":-0.042163},{"month":4,"riseRate":0.375,"avgChangeRate":0.027807},{"month":5,"riseRate":0.625,"avgChangeRate":-0.008066},{"month":6,"riseRate":0.777778,"avgChangeRate":0.082328},{"month":7,"riseRate":0.666667,"avgChangeRate":0.065113},{"month":8,"riseRate":0.555556,"avgChangeRate":0.035162},{"month":9,"riseRate":0.444444,"avgChangeRate":0.004414},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.091239},{"month":11,"riseRate":0.875,"avgChangeRate":0.192866},{"month":12,"riseRate":0.5,"avgChangeRate":0.028542}],"exchange":"NASDAQ","name":"Kiniksa Pharmaceuticals Ltd.","nameEN":"Kiniksa Pharmaceuticals Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kiniksa Pharmaceuticals Ltd.(KNSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kiniksa Pharmaceuticals Ltd.(KNSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kiniksa Pharmaceuticals Ltd.,KNSA,Kiniksa Pharmaceuticals Ltd.股票,Kiniksa Pharmaceuticals Ltd.股票老虎,Kiniksa Pharmaceuticals Ltd.股票老虎国际,Kiniksa Pharmaceuticals Ltd.行情,Kiniksa Pharmaceuticals Ltd.股票行情,Kiniksa Pharmaceuticals Ltd.股价,Kiniksa Pharmaceuticals Ltd.股市,Kiniksa Pharmaceuticals Ltd.股票价格,Kiniksa Pharmaceuticals Ltd.股票交易,Kiniksa Pharmaceuticals Ltd.股票购买,Kiniksa Pharmaceuticals Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kiniksa Pharmaceuticals Ltd.(KNSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kiniksa Pharmaceuticals Ltd.(KNSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}